Article
Oncology
Weimin Huang, Xiaolei Wei, Qi Wei, Yongqiang Wei, Ru Feng
Summary: Partial immunoparesis was found in 63% of MM patients, significantly associated with elevated B2M levels, decreased eGFR, and progressive ISS stage. It was identified as an independent prognostic factor for early grade >= 3 infections in MM patients, potentially improving infection risk models.
TRANSLATIONAL CANCER RESEARCH
(2021)
Review
Oncology
Michael Chahin, Zachery Branham, Ashley Fox, Christian Leurinda, Amany R. Keruakous
Summary: Immunoparesis, or the suppression of uninvolved immunoglobulins, is an important prognostic factor in multiple myeloma. It is associated with shorter overall survival and increased risk of relapse. Understanding the extent of immunoparesis is crucial in the management of multiple myeloma.
Article
Oncology
Jose Luis Garcia de Veas Silva, Maria Trinidad Gonzalez Cejudo, Alberto Garcia Perojil Jimenez, Maria del Senor Garcia Lopez Velez, Rafael Garcia Rios Tamayo, Carmen Garcia Bermudo Guitarte, Tomas Garcia De Haro Munoz
Summary: Despite significant advancements in Multiple Myeloma treatment, it remains incurable. A study found that HLC pair suppression is associated with a higher risk of life-threatening infections and early death in newly diagnosed MM patients, particularly in those over 65 with extreme suppression and bloodstream infections.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Jill Corre, Nikhil C. Munshi, Herve Avet-Loiseau
Summary: Although therapeutic strategies for multiple myeloma patients have been adapted based on age and comorbidities, high-risk patients still lack efficient treatment options. There is an urgent need to revise the current definition of risk in order to provide more effective drug combinations for these patients.
Article
Hematology
Matthew Ho, Saurabh Zanwar, Francis K. Buadi, Sikander Ailawadhi, Jeremy Larsen, Leif Bergsagel, Moritz Binder, Asher Chanan-Khan, David Dingli, Angela Dispenzieri, Rafael Fonseca, Morie A. Gertz, Wilson Gonsalves, Ronald S. Go, Suzanne Hayman, Prashant Kapoor, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Eli Muchtar, Vivek Roy, Taimur Sher, Rahma Warsame, Amie Fonder, Miriam Hobbs, Yi L. Hwa, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar
Summary: Patients with multiple myeloma have a lower efficacy from COVID-19 vaccination and a high rate of mortality from COVID-19 in hospitalized patients. The study found a relatively low infection rate but a quarter of the COVID-19 infections were severe. Treatment with CD38 antibody, cardiac and pulmonary comorbidities were independent predictors for ICU admission. Cardiac comorbidity was an independent predictor of mortality, while MM/AL in remission was associated with lower mortality.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Jessica Caro, David Cairns, Tom Menzies, Eileen Boyle, Charlotte Pawlyn, Gordon Cook, Martin Kaiser, Brian A. Walker, Roger Owen, Graham H. Jackson, Gareth J. Morgan, Jennifer Heaney, Mark Drayson, Faith E. Davies
Summary: Immunoparesis is associated with poor survival in myeloma. This study demonstrates that the etiologic cytogenetic abnormality influences the degree and clinical impact of immunoparesis in newly diagnosed patients in a large clinical trial. The depth of IgM immunoparesis can be used to further risk-stratify hyperdiploid patients for future clinical decisions.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Review
Biochemistry & Molecular Biology
Dominika Bebnowska, Rafal Hrynkiewicz, Ewelina Grywalska, Marcin Pasiarski, Barbara Sosnowska-Pasiarska, Iwona Smarz-Widelska, Stanislaw Gozdz, Jacek Rolinski, Paulina Niedzwiedzka-Rystwej
Summary: The article discusses the prognostic value of immune system components in patients with multiple myeloma to aid in the development of new diagnostic and therapeutic directions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Health Care Sciences & Services
Chuanying Geng, Guangzhong Yang, Huixing Zhou, Huijuan Wang, Yanchen Li, Yun Leng, Zhiyao Zhang, Yuan Jian, Wenming Chen
Summary: This study aimed to analyze the clinical characteristics and risk factors of ultra-high-risk (UHR) patients with newly diagnosed multiple myeloma (MM). Results showed that age > 65 years, LDH > 250 U/L, CsCa > 2.75 mmol/L, BNP or NT-proBNP > 2 ULN, high-risk cytogenetics, and Barthel index score were independent risk factors for UHR MM. UHR patients also had a worse response rate than control patients. These findings emphasize the importance of recognizing the characteristics and poor outcomes of UHR MM patients.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Hematology
Elena Zamagni, Simona Barbato, Michele Cavo
Summary: This article discusses the definitions of high-risk multiple myeloma (MM), trial results, and risk-adapted treatment strategies. For difficult-to-treat patients, therapy should be tailored based on relevant risk factors and biological characteristics.
Article
Oncology
Chuanying Geng, Guangzhong Yang, Huijuan Wang, Yin Wu, Yun Leng, Huixing Zhou, Zhiyao Zhang, Yuan Jian, Wenming Chen
Summary: The study demonstrated that deep and partial immunoparesis in patients with newly diagnosed multiple myeloma is an independent poor prognostic factor, leading to shorter overall survival and progression-free survival. Matching analysis revealed consistent results, further emphasizing the significance of immunoparesis in predicting survival outcomes.
LEUKEMIA & LYMPHOMA
(2021)
Article
Biochemistry & Molecular Biology
Yapeng Su, Dan Yuan, Daniel G. Chen, Rachel H. Ng, Kai Wang, Jongchan Choi, Sarah Li, Sunga Hong, Rongyu Zhang, Jingyi Xie, Sergey A. Kornilov, Kelsey Scherler, Ana Jimena Pavlovitch-Bedzyk, Shen Dong, Christopher Lausted, Inyoul Lee, Shannon Fallen, Chengzhen L. Dai, Priyanka Baloni, Brett Smith, Venkata R. Duvvuri, Kristin G. Anderson, Jing Li, Fan Yang, Caroline J. Duncombe, Denise J. McCulloch, Clifford Rostomily, Pamela Troisch, Jing Zhou, Sean Mackay, Quinn DeGottardi, Damon H. May, Ruth Taniguchi, Rachel M. Gittelman, Mark Klinger, Thomas M. Snyder, Ryan Roper, Gladys Wojciechowska, Kim Murray, Rick Edmark, Simon Evans, Lesley Jones, Yong Zhou, Lee Rowen, Rachel Liu, William Chour, Heather A. Algren, William R. Berrington, Julie A. Wallick, Rebecca A. Cochran, Mary E. Micikas, Terri Wrin, Christos J. Petropoulos, Hunter R. Cole, Trevan D. Fischer, Wei Wei, Dave S. B. Hoon, Nathan D. Price, Naeha Subramanian, Joshua A. Hill, Jennifer Hadlock, Andrew T. Magis, Antoni Ribas, Lewis L. Lanier, Scott D. Boyd, Jeffrey A. Bluestone, Helen Chu, Leroy Hood, Raphael Gottardo, Philip D. Greenberg, Mark M. Davis, Jason D. Goldman, James R. Heath
Summary: Post-acute sequelae of COVID-19 (PASC) is an emerging global crisis, and the quantifiable risk factors and biological associations are not well understood. In this study, a deep multi-omic investigation was conducted on 309 COVID-19 patients, and four PASC-anticipating risk factors were identified at the time of initial diagnosis. The study also observed changes in immune states during recovery from COVID-19.
Article
Medicine, General & Internal
Damian Mikulski, Pawel Robak, Wiktoria Ryzewska, Kamila Stanczak, Kacper Koscielny, Joanna Gora-Tybor, Tadeusz Robak
Summary: This study examines the clinical factors influencing the occurrence of infection in MM patients treated with lenalidomide and dexamethasone. The analysis found hypoalbuminemia, autologous hematopoietic stem cell transplantation (AHSCT) before Rd, and anemia grade >= 3 to be independent factors related to the occurrence of infections.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Wenjiao Tang, Jinrong Yang, Yan Li, Li Zhang, He Li, Jie Wang, Yi Liao, Chunlan Zhang, Ying Qu, Yuhuan Zheng, Ting Niu
Summary: This study investigated the attrition rates and risk factors of subsequent line of therapy (LOT) in Chinese multiple myeloma (MM) patients. The results showed that attrition rates increased gradually across all LOTs, and higher tumor burden and comorbidities may result in fewer subsequent LOTs. The findings highlight the importance of choosing the optimal frontline treatment regimen over salvaging subsequent LOTs.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Respiratory System
Bhim Gopal Dhoubhadel, Motoi Suzuki, Tomoko Ishifuji, Makito Yaegashi, Norichika Asoh, Masayuki Ishida, Sugihiro Hamaguchi, Masahiro Aoshima, Michio Yasunami, Koya Ariyoshi, Konosuke Morimoto
Summary: This study found that multiple serotypes of pneumococci are common among adults with pneumonia. The risk of multiple-serotype pneumococcal pneumonia is lower in patients vaccinated with PPSV23. Certain specific serotypes are associated with multiple-serotype pneumonia, and more invasive serotypes are more prevalent in multiple-serotype pneumonia.
Review
Medicine, General & Internal
Niels W. C. J. van de Donk, Charlotte Pawlyn, Kwee L. Yong
Summary: Multiple myeloma is the second most common haematological malignancy in high-income countries. Current treatment strategies have extended patient survival, but the majority will ultimately die from the disease. Diagnostics and risk stratification are crucial for prognosis and treatment strategies.
Article
Hematology
Sonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard M. J. Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette W. G. van der Velden, Wendy Deenik, Astrid Gruber, Juleon L. L. M. Coenen, Torben Plesner, Saskia K. Klein, Bea C. Tanis, Damian L. Szatkowski, Rolf E. Brouwer, Matthijs Westerman, M. (Rineke) B. L. Leys, Harm A. M. Sinnige, Einar Haukas, Klaas G. van der Hem, Marc F. Durian, E. (Vera) J. M. Mattijssen, Niels W. C. J. van de Donk, Marian J. P. L. Stevens-Kroef, Pieter Sonneveld, Anders Waage
Article
Hematology
Rasmus Sorrig, Tobias W. Klausen, Morten Salomo, Annette Vangsted, Peter Gimsing
EUROPEAN JOURNAL OF HAEMATOLOGY
(2018)
Article
Multidisciplinary Sciences
Rasmus Sorrig, Tobias W. Klausen, Morten Salomo, Annette J. Vangsted, Ulf Christian Frolund, Kristian T. Andersen, Anja Klostergaard, Carsten Helleberg, Robert S. Pedersen, Per T. Pedersen, Sissel Helm-Petersen, Elena Manuela Teodorescu, Birgitte Preiss, Niels Abildgaard, Peter Gimsing
Article
Medicine, General & Internal
Meletios A. Dimopoulos, Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, Hartmut Goldschmidt, Vladimir Maisnar, Philippe Moreau, Chang Ki Min, Agnieszka Pluta, Wee-Joo Chng, Martin Kaiser, Sonja Zweegman, Maria-Victoria Mateos, Andrew Spencer, Shinsuke Iida, Gareth Morgan, Kaveri Suryanarayan, Zhaoyang Teng, Tomas Skacel, Antonio Palumbo, Ajeeta B. Dash, Neeraj Gupta, Richard Labotka, S. Vincent Rajkumar, Daniel Bar, Alfredo Basso, Dorotea Fantl, Simon He, Neomi Horvath, Cindy Lee, Phillip Rowlings, Kerry Taylor, Tara Cochrane, Fiona Kwok, Sundreswran Ramanathan, Hermine Agis, Niklas Zojer, Alain Kentos, Fritz Offner, Jan Van Droogenbroeck, Ka Lung Wu, Angelo Maiolino, Gracia Martinez, Karla Zanella, Marcelo Capra, Sergio Araujo, Evzen Gregora, Ludek Pour, Vlastimil Scudla, Ivan Spicka, Niels Abildgaard, Niels Andersen, Bo Amdi Jensen, Carsten Helleberg, Torben Plesner, Morten Salomo, Asta Svirskaite, Richard Delarue, Igor Blau, Aneta Schieferdecker, Veronica Teleanu, Markus Munder, Christoph Rollig, Han-Juergen Salwender, Stephan Fuhrmann, Katja Weisel, Jan Duerig, Matthias Zeis, Stefan Klein, Peter Reimer, Christian Schmidt, Christof Scheid, Karin Mayer, Martin Hoffmann, Markus Sosada, Athanasios Dimopoulos, Sosana Delimpasi, Mary-Christine Kyrtsonis, Achilleas Anagnostopoulos, Zsolt Nagy, Arpad Illes, Miklos Egyed, Zita Borbenyi, Gabor Mikala, Najib Dally, Netanel Horowitz, Odit Gutwein, Anatoly Nemets, Iuliana Vaxman, Olga Shvetz, Svetlana Trestman, Rosa Ruchlemer, Arnon Nagler, Tamar Tadmor, Ory Rouvio, Meir Preis, Michele Cavo, Luca De Rosa, Pellegrino Musto, Anna Cafro, Patrizia Tosi, Massimo Offidani, Alessandro Corso, Giuseppe Rossi, Anna Marina Liberati, Alberto Bosi, Kenshi Suzuki, Chiaki Nakaseko, Takayuki Ishikawa, Morio Matsumoto, Hirokazu Nagai, Kazutaka Sunami, Takaaki Chou, Koichi Akashi, Naoki Takezako, Shotaro Hagiwara, Hyeon Seok Eom, Deog-Yeon Jo, Jin Seok Kim, Jae Hoon Lee, Sung Soo Yoon, Dok Hyun Yoon, Kihyun Kim, Mark-David Levin, Edo Vellenga, Monique Minnema, Anders Waage, Einar Haukas, Sebastian Grosicki, Andrzej Pluta, Tadeusz Robak, Herlander Marques, Rui Bergantim, Fernando Campilho, Wee Joo Chng, Yeow Tee Goh, Andrew McDonald, Bernado Rapoport, Miguel Angel Alvarez Rivas, Felipe De Arriba de La Fuente, Yolanda Gonzalez Montes, Jesus Martin Sanchez, Maria Victoria Mateos, Albert Oriol Rocafiguera, Laura Rosinol, Jesus San Miguel, Jaime Perez de Oteyza, Cristina Encinas, Adrian Alegre-Amor, Ana Lopez-Guia, Per Axelsson, Kristina Carlson, Olga Stromberg, Markus Hansson, Cecile Hveding Blimark, Rouven Mueller, Chih-Cheng Chen, Ta-Chih Liu, Shang-Yi Huang, Po-Nan Wang, Thanyaphong Na Nakorn, Kannadit Prayongratana, Ali Unal, Hakan Goker, Mehmet Sonmez, Sybiryna Korenkova, Aristeidis Chaidos, Heather Oakervee, Hamdi Sati, Reuben Benjamin, Ashutosh Wechalekar, Mamta Garg, Karthik Ramasamy, Gordon Cook, Andrew Chantry, Matthew Jenner, Francis Buadi, Robert Berryman, Murali Janakiram
Letter
Ophthalmology
Peter K. Rasmussen, Jens F. Kiilgaard, Morten Salomo
JAMA OPHTHALMOLOGY
(2019)
Article
Oncology
Paul G. Richardson, Albert Oriol, Meral Beksac, Anna Marina Liberati, Monica Galli, Fredrik Schjesvold, Jindriska Lindsay, Katja Weisel, Darrell White, Thierry Facon, Jesus Son Miguel, Kazutaka Sunami, Peter O'Gorman, Pieter Sonneveld, Pawel Robak, Sergey Semochkin, Steve Schey, Xin Yu, Thomas Doerr, Amine Bensmaine, Tsvetan Biyukov, Teresa Peluso, Mohamed Zaki, Kenneth Anderson, Meletios Dimopoulos
Article
Hematology
Lene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette van der Velden, Wendy Deenik, Juleon Coenen, Maja Hinge, Saskia Klein, Bea Tanis, Damian Szatkowski, Rolf Brouwer, Matthijs Westerman, Rineke Leys, Harm Sinnige, Einar Haukas, Klaas van der Hem, Marc Durian, Peter Gimsing, Niels van de Donk, Pieter Sonneveld, Anders Waage, Niels Abildgaard, Sonja Zweegman
Letter
Hematology
Sonja Zweegman, Claudia A. M. Stege, Einar Haukas, Fredrik H. Schjesvold, Mark-David Levin, Anders Waage, Rineke B. L. Leys, Saskia K. Klein, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Dorota Knut-Bojanowska, Ellen van der Spek, Asta Svirskaite, Anja Klostergaard, Morten Salomo, Celine Blimark, Paula F. Ypma, Ulf-Hendrik Mellqvist, Pino J. Poddighe, Marian Stevens-Kroef, Niels W. C. J. van de Donk, Pieter Sonneveld, Markus Hansson, Bronno van der Holt, Niels Abildgaard
Article
Hematology
Louise Redder, Tobias W. Klausen, Annette Juul Vangsted, Henrik Gregersen, Niels F. Andersen, Robert S. Pedersen, Agoston G. Szabo, Mikael Frederiksen, Ulf C. Frolund, Carsten Helleberg, Lene Kongsgaard Nielsen, Per T. Pedersen, Morten Salomo, Peter Gimsing, Henrik Frederiksen, Niels Abildgaard
Summary: The study validated the predictive value of MRP in transplant ineligible MM patients above 65 years, stratifying patients into different risk groups and showing a higher risk of early death in high-risk patients compared to low-risk patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Meletios Dimopoulos, Katja Weisel, Philippe Moreau, Larry D. Anderson, Darrell White, Jesus San-Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Duerig, Michel Pavic, Morten Salomo, Eva Casal, Shankar Srinivasan, Xin Yu, Tuong Vi Nguyen, Tsvetan Biyukov, Teresa Peluso, Paul Richardson
Summary: In the phase 3 OPTIMISMM trial, PVd showed superior efficacy compared to Vd in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide. Second-line PVd significantly improved progression-free survival (PFS) in lenalidomide-refractory and lenalidomide-nonrefractory patients, regardless of prior bortezomib exposure or stem cell transplant history.
Article
Hematology
Paul G. Richardson, Fredrik Schjesvold, Katja Weisel, Philippe Moreau, Larry D. Anderson, Darrell White, Paula Rodriguez-Otero, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Duerig, Michel Pavic, Morten Salomo, Meral Beksac, Albert Oriol, Jindriska Lindsay, Anna Marina Liberati, Monica Galli, Pawel Robak, Alessandra Larocca, Munci Yagci, Filiz Vural, Abraham S. Kanate, Ruiyun Jiang, Lara Grote, Teresa Peluso, Meletios Dimopoulos
Summary: This study showed that PVd significantly prolonged PFS in lenalidomide-pretreated patients with multiple myeloma at first relapse, across different age groups, renal function status, and cytogenetic abnormalities. PVd also improved overall response rate in all subgroups, with a safety profile consistent with previous reports.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2022)
Article
Medicine, General & Internal
E. Kastritis, G. Palladini, M. C. Minnema, A. D. Wechalekar, A. Jaccard, H. C. Lee, V Sanchorawala, S. Gibbs, P. Mollee, C. P. Venner, J. Lu, S. Schonland, M. E. Gatt, K. Suzuki, K. Kim, M. T. Cibeira, M. Beksac, E. Libby, J. Valent, V Hungria, S. W. Wong, M. Rosenzweig, N. Bumma, A. Huart, M. A. Dimopoulos, D. Bhutani, A. J. Waxman, S. A. Goodman, J. A. Zonder, S. Lam, K. Song, T. Hansen, S. Manier, W. Roeloffzen, K. Jamroziak, F. Kwok, C. Shimazaki, J-S Kim, E. Crusoe, T. Ahmadi, N. P. Tran, X. Qin, S. Y. Vasey, B. Tromp, J. M. Schecter, B. M. Weiss, S. H. Zhuang, J. Vermeulen, G. Merlini, R. L. Comenzo
Summary: In patients with newly diagnosed AL amyloidosis, adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone resulted in higher rates of hematologic complete response and improved survival outcomes. However, adverse events, including lymphopenia, pneumonia, cardiac failure, and diarrhea, were more common in the daratumumab group. Most deaths were due to amyloidosis-related cardiomyopathy.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Oscar Westin, Jawad H. Butt, Finn Gustafsson, Morten Schou, Morten Salomo, Lars Kober, Mathew Maurer, Emil L. Fosbol
Summary: This study in Denmark showed an increasing diagnosis of cardiac amyloidosis, with a higher proportion of male patients and older age at diagnosis over the period of 1998 to 2017. There was also a decrease in 2-year mortality rates among the patients with cardiac amyloidosis.
JACC: CARDIOONCOLOGY
(2021)
Article
Medicine, General & Internal
Christoffer Galletta Rene, Michael Patrick Achiam, Morten Salomo, Luit Penninga
Summary: The case study presented a 74-year-old male patient with multiple myeloma who relapsed with extramedullary manifestations, including gastric plasmacytoma. After successful chemoradiotherapy for 8 months, the patient's condition deteriorated, leading to palliative care and eventual death 10 months after surgery.Prospective studies are needed to improve the poor prognosis of extramedullary multiple myeloma.
